AstraZeneca PLC - American Depositary Shares (NY:AZN)

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

From AstraZeneca

Performance

52-Week Range 26.3% below 52-week high

156.68

153.4152W Low 212.7152W High

1 Week 6.5% below 1-week high

157.541W Low 167.521W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $153.41 and $212.71 over the past 52 weeks and last traded at $156.68, 26.3% below its 52-week high. Over the past week it ranged between $157.54 and $167.52.

Past 12 Months

-5.9%

-3.6%

-19.7%

-23.0%

-16.8%

1W -$9.90

1M -$5.79

3M -$38.47

6M -$46.81

YTD -$31.73

1Y -$31.73

AZN was -16.8% over the past year, -23.0% over six months, -16.8% year to date, -5.9% in the last week.

12 Months vs Market

AZN

-16.8%

DIA

+10.1%

SPY

+15.2%

QQQ

+24.4%

IWM

+16.3%

Over the past 12 months AZN returned -16.8% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +24.4% and IWM (Russell 2000) +16.3%.

Volume & Liquidity 0.36× 3-mo avg

Today 1,229,727 3-mo avg 3.4M

2.6M

3.0M

3.4M

2.7M

YTD

2.6M

AZN most recently traded 1,229,727 shares against a 3-month average daily volume of 3.4M.

More News

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

September 13, 2026

From AstraZeneca

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026

From AstraZeneca

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗

September 13, 2026

Via MarketBeat

September 08, 2026

From AstraZeneca

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 08, 2026

From AstraZeneca

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 04, 2026

From AstraZeneca

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

September 01, 2026

From AstraZeneca

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

August 27, 2026

From AstraZeneca

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

From MarketNewsUpdates.com

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

From USA News Group

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

August 17, 2026

From AstraZeneca

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

August 17, 2026

From AstraZeneca

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

August 04, 2026

From Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

July 28, 2026

From Pomerantz LLP

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Astrazeneca Q2 Earnings Call Highlights ↗

July 27, 2026

Via MarketBeat

July 27, 2026

From AstraZeneca

AstraZeneca results: H1 and Q2 2026

July 27, 2026

From AstraZeneca